Mode and site of action of therapies targeting CGRP signaling
Abstract Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatment...
| 出版年: | The Journal of Headache and Pain |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
BMC
2023-09-01
|
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s10194-023-01644-8 |
| _version_ | 1851901281182941184 |
|---|---|
| author | Alejandro Labastida-Ramírez Edoardo Caronna Cédric Gollion Emily Stanyer Austeja Dapkute Diana Braniste Hoda Naghshineh Liga Meksa Nino Chkhitunidze Tamari Gudadze Patricia Pozo-Rosich Rami Burstein Jan Hoffmann |
| author_facet | Alejandro Labastida-Ramírez Edoardo Caronna Cédric Gollion Emily Stanyer Austeja Dapkute Diana Braniste Hoda Naghshineh Liga Meksa Nino Chkhitunidze Tamari Gudadze Patricia Pozo-Rosich Rami Burstein Jan Hoffmann |
| author_sort | Alejandro Labastida-Ramírez |
| collection | DOAJ |
| container_title | The Journal of Headache and Pain |
| description | Abstract Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and/or switching between these therapies are addressed. |
| format | Article |
| id | doaj-art-e362add4199b46bbb5eb14bc92a5cd98 |
| institution | Directory of Open Access Journals |
| issn | 1129-2377 |
| language | English |
| publishDate | 2023-09-01 |
| publisher | BMC |
| record_format | Article |
| spelling | doaj-art-e362add4199b46bbb5eb14bc92a5cd982025-08-19T22:05:44ZengBMCThe Journal of Headache and Pain1129-23772023-09-0124111410.1186/s10194-023-01644-8Mode and site of action of therapies targeting CGRP signalingAlejandro Labastida-Ramírez0Edoardo Caronna1Cédric Gollion2Emily Stanyer3Austeja Dapkute4Diana Braniste5Hoda Naghshineh6Liga Meksa7Nino Chkhitunidze8Tamari Gudadze9Patricia Pozo-Rosich10Rami Burstein11Jan Hoffmann12Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology & Neuroscience, King’s College LondonHeadache Unit, Neurology Department, Vall d’Hebron Universitary HospitalDepartment of Neurology, University Hospital of ToulouseWolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology & Neuroscience, King’s College LondonCentre of Neurology, Vilnius UniversityInstitute of Neurology and NeurosurgeryHeadache Department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical ScienceHeadache Unit, Neurology and Neurosurgery Department, Riga East University Hospital GailezersDepartment of Neurology, Caucasus Medical CentreDepartment of Neurology, Christian Hospital UnnaHeadache Unit, Neurology Department, Vall d’Hebron Universitary HospitalDepartment of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical CenterWolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology & Neuroscience, King’s College LondonAbstract Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and/or switching between these therapies are addressed.https://doi.org/10.1186/s10194-023-01644-8AmylinAnti-CGRPCalcitoninHeadacheMigraineTrigeminal |
| spellingShingle | Alejandro Labastida-Ramírez Edoardo Caronna Cédric Gollion Emily Stanyer Austeja Dapkute Diana Braniste Hoda Naghshineh Liga Meksa Nino Chkhitunidze Tamari Gudadze Patricia Pozo-Rosich Rami Burstein Jan Hoffmann Mode and site of action of therapies targeting CGRP signaling Amylin Anti-CGRP Calcitonin Headache Migraine Trigeminal |
| title | Mode and site of action of therapies targeting CGRP signaling |
| title_full | Mode and site of action of therapies targeting CGRP signaling |
| title_fullStr | Mode and site of action of therapies targeting CGRP signaling |
| title_full_unstemmed | Mode and site of action of therapies targeting CGRP signaling |
| title_short | Mode and site of action of therapies targeting CGRP signaling |
| title_sort | mode and site of action of therapies targeting cgrp signaling |
| topic | Amylin Anti-CGRP Calcitonin Headache Migraine Trigeminal |
| url | https://doi.org/10.1186/s10194-023-01644-8 |
| work_keys_str_mv | AT alejandrolabastidaramirez modeandsiteofactionoftherapiestargetingcgrpsignaling AT edoardocaronna modeandsiteofactionoftherapiestargetingcgrpsignaling AT cedricgollion modeandsiteofactionoftherapiestargetingcgrpsignaling AT emilystanyer modeandsiteofactionoftherapiestargetingcgrpsignaling AT austejadapkute modeandsiteofactionoftherapiestargetingcgrpsignaling AT dianabraniste modeandsiteofactionoftherapiestargetingcgrpsignaling AT hodanaghshineh modeandsiteofactionoftherapiestargetingcgrpsignaling AT ligameksa modeandsiteofactionoftherapiestargetingcgrpsignaling AT ninochkhitunidze modeandsiteofactionoftherapiestargetingcgrpsignaling AT tamarigudadze modeandsiteofactionoftherapiestargetingcgrpsignaling AT patriciapozorosich modeandsiteofactionoftherapiestargetingcgrpsignaling AT ramiburstein modeandsiteofactionoftherapiestargetingcgrpsignaling AT janhoffmann modeandsiteofactionoftherapiestargetingcgrpsignaling |